430 related articles for article (PubMed ID: 30790227)
1. Clinical significance of metabolism-related biomarkers in non-Hodgkin lymphoma - MCT1 as potential target in diffuse large B cell lymphoma.
Afonso J; Pinto T; Simões-Sousa S; Schmitt F; Longatto-Filho A; Pinheiro C; Marques H; Baltazar F
Cell Oncol (Dordr); 2019 Jun; 42(3):303-318. PubMed ID: 30790227
[TBL] [Abstract][Full Text] [Related]
2. Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer.
Polański R; Hodgkinson CL; Fusi A; Nonaka D; Priest L; Kelly P; Trapani F; Bishop PW; White A; Critchlow SE; Smith PD; Blackhall F; Dive C; Morrow CJ
Clin Cancer Res; 2014 Feb; 20(4):926-937. PubMed ID: 24277449
[TBL] [Abstract][Full Text] [Related]
3. Hodgkin lymphoma: A complex metabolic ecosystem with glycolytic reprogramming of the tumor microenvironment.
Mikkilineni L; Whitaker-Menezes D; Domingo-Vidal M; Sprandio J; Avena P; Cotzia P; Dulau-Florea A; Gong J; Uppal G; Zhan T; Leiby B; Lin Z; Pro B; Sotgia F; Lisanti MP; Martinez-Outschoorn U
Semin Oncol; 2017 Jun; 44(3):218-225. PubMed ID: 29248133
[TBL] [Abstract][Full Text] [Related]
4. Cancer metabolism, stemness and tumor recurrence: MCT1 and MCT4 are functional biomarkers of metabolic symbiosis in head and neck cancer.
Curry JM; Tuluc M; Whitaker-Menezes D; Ames JA; Anantharaman A; Butera A; Leiby B; Cognetti DM; Sotgia F; Lisanti MP; Martinez-Outschoorn UE
Cell Cycle; 2013 May; 12(9):1371-84. PubMed ID: 23574725
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of monocarboxyate transporter 1 by AZD3965 as a novel therapeutic approach for diffuse large B-cell lymphoma and Burkitt lymphoma.
Noble RA; Bell N; Blair H; Sikka A; Thomas H; Phillips N; Nakjang S; Miwa S; Crossland R; Rand V; Televantou D; Long A; Keun HC; Bacon CM; Bomken S; Critchlow SE; Wedge SR
Haematologica; 2017 Jul; 102(7):1247-1257. PubMed ID: 28385782
[TBL] [Abstract][Full Text] [Related]
6. Mitochondrial and glycolytic metabolic compartmentalization in diffuse large B-cell lymphoma.
Gooptu M; Whitaker-Menezes D; Sprandio J; Domingo-Vidal M; Lin Z; Uppal G; Gong J; Fratamico R; Leiby B; Dulau-Florea A; Caro J; Martinez-Outschoorn U
Semin Oncol; 2017 Jun; 44(3):204-217. PubMed ID: 29248132
[TBL] [Abstract][Full Text] [Related]
7. CD147 subunit of lactate/H+ symporters MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth of glycolytic tumors.
Le Floch R; Chiche J; Marchiq I; Naiken T; Ilc K; Murray CM; Critchlow SE; Roux D; Simon MP; Pouysségur J
Proc Natl Acad Sci U S A; 2011 Oct; 108(40):16663-8. PubMed ID: 21930917
[TBL] [Abstract][Full Text] [Related]
8. MCT1 Inhibitor AZD3965 Increases Mitochondrial Metabolism, Facilitating Combination Therapy and Noninvasive Magnetic Resonance Spectroscopy.
Beloueche-Babari M; Wantuch S; Casals Galobart T; Koniordou M; Parkes HG; Arunan V; Chung YL; Eykyn TR; Smith PD; Leach MO
Cancer Res; 2017 Nov; 77(21):5913-5924. PubMed ID: 28923861
[TBL] [Abstract][Full Text] [Related]
9. In Vivo Anticancer Activity of AZD3965: A Systematic Review.
Silva A; Antunes B; Batista A; Pinto-Ribeiro F; Baltazar F; Afonso J
Molecules; 2021 Dec; 27(1):. PubMed ID: 35011413
[TBL] [Abstract][Full Text] [Related]
10. Coexpression of MCT1 and MCT4 in ALK-positive Anaplastic Large Cell Lymphoma: Diagnostic and Therapeutic Implications.
Choi JW; Lee Y; Kim H; Cho HY; Min SK; Kim YS
Am J Surg Pathol; 2022 Feb; 46(2):241-248. PubMed ID: 34619707
[TBL] [Abstract][Full Text] [Related]
11. Cellular Uptake of MCT1 Inhibitors AR-C155858 and AZD3965 and Their Effects on MCT-Mediated Transport of L-Lactate in Murine 4T1 Breast Tumor Cancer Cells.
Guan X; Rodriguez-Cruz V; Morris ME
AAPS J; 2019 Jan; 21(2):13. PubMed ID: 30617815
[TBL] [Abstract][Full Text] [Related]
12. MCT1 Modulates Cancer Cell Pyruvate Export and Growth of Tumors that Co-express MCT1 and MCT4.
Hong CS; Graham NA; Gu W; Espindola Camacho C; Mah V; Maresh EL; Alavi M; Bagryanova L; Krotee PAL; Gardner BK; Behbahan IS; Horvath S; Chia D; Mellinghoff IK; Hurvitz SA; Dubinett SM; Critchlow SE; Kurdistani SK; Goodglick L; Braas D; Graeber TG; Christofk HR
Cell Rep; 2016 Feb; 14(7):1590-1601. PubMed ID: 26876179
[TBL] [Abstract][Full Text] [Related]
13. Organized metabolic crime in prostate cancer: The coexpression of MCT1 in tumor and MCT4 in stroma is an independent prognosticator for biochemical failure.
Andersen S; Solstad Ø; Moi L; Donnem T; Eilertsen M; Nordby Y; Ness N; Richardsen E; Busund LT; Bremnes RM
Urol Oncol; 2015 Aug; 33(8):338.e9-17. PubMed ID: 26066969
[TBL] [Abstract][Full Text] [Related]
14. Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of Resistance.
Quanz M; Bender E; Kopitz C; Grünewald S; Schlicker A; Schwede W; Eheim A; Toschi L; Neuhaus R; Richter C; Toedling J; Merz C; Lesche R; Kamburov A; Siebeneicher H; Bauser M; Hägebarth A
Mol Cancer Ther; 2018 Nov; 17(11):2285-2296. PubMed ID: 30115664
[TBL] [Abstract][Full Text] [Related]
15. Expression of lactate/H⁺ symporters MCT1 and MCT4 and their chaperone CD147 predicts tumor progression in clear cell renal cell carcinoma: immunohistochemical and The Cancer Genome Atlas data analyses.
Kim Y; Choi JW; Lee JH; Kim YS
Hum Pathol; 2015 Jan; 46(1):104-12. PubMed ID: 25456395
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical evaluation and prognostic value of monocarboxylate transporter 1 (MCT1) and 4 (MCT4) in T-cell non-Hodgkin lymphoma.
Zhao H; Chen Y; Liao YP; Chen HM; Yang QH; Xiao Y; Luo J; Chen ZZ; Yi L; Hu GY
Clin Exp Med; 2023 Feb; 23(1):55-64. PubMed ID: 35239073
[TBL] [Abstract][Full Text] [Related]
17. Clinically relevant HIF-1α-dependent metabolic reprogramming in oropharyngeal squamous cell carcinomas includes coordinated activation of CAIX and the miR-210/ISCU signaling axis, but not MCT1 and MCT4 upregulation.
Sáenz-de-Santa-María I; Bernardo-Castiñeira C; Secades P; Bernaldo-de-Quirós S; Rodrigo JP; Astudillo A; Chiara MD
Oncotarget; 2017 Feb; 8(8):13730-13746. PubMed ID: 28099149
[TBL] [Abstract][Full Text] [Related]
18. Monocarboxylate transporter 1 and 4 inhibitors as potential therapeutics for treating solid tumours: A review with structure-activity relationship insights.
Puri S; Juvale K
Eur J Med Chem; 2020 Aug; 199():112393. PubMed ID: 32388280
[TBL] [Abstract][Full Text] [Related]
19. The two glycolytic markers GLUT1 and MCT1 correlate with tumor grade and survival in clear-cell renal cell carcinoma.
Ambrosetti D; Dufies M; Dadone B; Durand M; Borchiellini D; Amiel J; Pouyssegur J; Rioux-Leclercq N; Pages G; Burel-Vandenbos F; Mazure NM
PLoS One; 2018; 13(2):e0193477. PubMed ID: 29481555
[TBL] [Abstract][Full Text] [Related]
20. Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt's lymphoma anti-tumor activity.
Curtis NJ; Mooney L; Hopcroft L; Michopoulos F; Whalley N; Zhong H; Murray C; Logie A; Revill M; Byth KF; Benjamin AD; Firth MA; Green S; Smith PD; Critchlow SE
Oncotarget; 2017 Sep; 8(41):69219-69236. PubMed ID: 29050199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
